In case you missed it

October 4, 2014

Web Version  |  Share with a colleague  |  eNews Subscribe

You are subscribed to the FormularyWatch eNews

In case you missed it
In case you missed it
FormularyWatch

First long-term treatment for DME approved by FDA

FDA has approved fluocinolone acetonide intravitreal implant (Iluvien, Alimera) 0.19 mg for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. » Read about this newly US-approved drug

FDA OKs Relistor for opioid-induced constipation in chronic non-cancer pain

FDA approved methylnaltrexone bromide (Relistor, Salix Pharmaceuticals and Progenics Pharmaceuticals) subcutaneous injection, 12 mg/0.6 mL, for the treatment of opioid-induced constipation in patients taking opioids for chronic non-cancer pain. » Read about the phase 3 trial on which the approval was based

In case you missed it

#icymiTwitter Facebook

In case you missed it
Powered by Modern Medicine Advanstar Medical Communications Group